:check:I have read similar stories lately. http://www.cnn.com/2014/03/10/health/cohen-josh/index.html?hpt=hp_c2
This is a perfect example of the undeniable greed and heartlessness of USA based pharmaceutical companies.
Just read the illogical explanation give by this company to--not--provide compassionate medicine.
It is enough to make kind people turn into anarchist.
Why Chimerix will not provide the drug = STOCKHOLDER will sell out and the market will devalue the stock.
The company has nothing to lose--it is already undervalued and a compassionate use is not going to drive it into bankruptcy. It may have been heading that way on its own. On the contrary, it ought to be a good PR move.
Of course, there is always more to the story.
http://www.chimerix.com/
Put Chimerix on your "greed list."
Company rationale:
Restricted Access Program
Over the past several years Chimerix has received hundreds of requests for the compassionate use of brincidofovir. Words are inadequate to express our empathy and concern for what individuals with life-threatening viral infections, and their families, are experiencing. This is why we are dedicated to demonstrating the safety and efficacy of brincidofovir in our ongoing Phase 3 SUPPRESS clinical trial - so that we can make brincidofovir available as soon as possible to the thousands of patients each year who might benefit from it.
Making an experimental drug available outside of controlled clinical trials has the potential to slow or derail the approval of that drug. Providing brincidofovir in any of these situations, where there is currently limited evidence to suggest that our experimental medicine would be helpful, could very likely place the entire development program at risk. The successful completion of SUPPRESS is the primary focus and mission of our small company.
The Biotechnology Industry Organization (BIO) has issued a document which sets forth BIO’s 4 principles for Compassionate Use Programs - “Early Access Programs: Points to Consider.”
This is a perfect example of the undeniable greed and heartlessness of USA based pharmaceutical companies.
Just read the illogical explanation give by this company to--not--provide compassionate medicine.
It is enough to make kind people turn into anarchist.
Why Chimerix will not provide the drug = STOCKHOLDER will sell out and the market will devalue the stock.
The company has nothing to lose--it is already undervalued and a compassionate use is not going to drive it into bankruptcy. It may have been heading that way on its own. On the contrary, it ought to be a good PR move.
Of course, there is always more to the story.
http://www.chimerix.com/
Put Chimerix on your "greed list."
Company rationale:
Restricted Access Program
Over the past several years Chimerix has received hundreds of requests for the compassionate use of brincidofovir. Words are inadequate to express our empathy and concern for what individuals with life-threatening viral infections, and their families, are experiencing. This is why we are dedicated to demonstrating the safety and efficacy of brincidofovir in our ongoing Phase 3 SUPPRESS clinical trial - so that we can make brincidofovir available as soon as possible to the thousands of patients each year who might benefit from it.
Making an experimental drug available outside of controlled clinical trials has the potential to slow or derail the approval of that drug. Providing brincidofovir in any of these situations, where there is currently limited evidence to suggest that our experimental medicine would be helpful, could very likely place the entire development program at risk. The successful completion of SUPPRESS is the primary focus and mission of our small company.
The Biotechnology Industry Organization (BIO) has issued a document which sets forth BIO’s 4 principles for Compassionate Use Programs - “Early Access Programs: Points to Consider.”
Last edited:
